We do not but have the expertise to treatment Alzheimer’s, health-care investor says
Ali Satvat, Jorge Conde, and Peter Orszag throughout a panel dialogue on the CNBC Wholesome Returns convention in New York on May 21, 2019.
Astrid Stawiarz | CNBC
Biotech firms do not but have the expertise or understanding of Alzheimer’s to discover a treatment for the illness that plagues virtually 5.eight million individuals within the U.S., Andreessen Horowitz normal associate Jorge Conde mentioned Tuesday at CNBC’s Wholesome Returns convention in New York.
“One of the things we look for when we make investments, we talked earlier about binary risk, is when developing a new therapeutic, you have to understand what the disease is doing,” he mentioned. “You have to understand what you need in it to affect the disease process and then you have to have the capability to actually make that molecule or that cell or that gene.”
With Alzheimer’s “we don’t even really know the very first layer, so the probability that you’re going to find the right target and hit it is going to be unlikely, unless we can get that first level of understanding the disease,” he mentioned.
Biogen earlier this yr joined a protracted record of firms within the final decade which have didn’t discover a treatment for Alzheimer’s illness. Earlier this yr, it halted the medical trial of Alzheimer’s drug aducanumab, which it was creating in partnership with Japanese pharmaceutical firm Eisai. Alzheimer’s is a progressive and debilitating illness that always impacts an individual’s reminiscence, pondering and conduct.
Alzheimer’s is “very, very difficult to solve and it’s going to require new technology to do it, and i just don’t think we have the technology,” Conde mentioned.